Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 665

1.

Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

Khan MM.

Vaccine. 2008 Apr 7;26(16):2034-40. doi: 10.1016/j.vaccine.2008.02.008. Epub 2008 Feb 22.

PMID:
18339460
2.

Cost analysis of post-polio certification immunization policies.

Sangrujee N, Cáceres VM, Cochi SL.

Bull World Health Organ. 2004 Jan;82(1):9-15. Epub 2004 Feb 26.

3.

The cost-effectiveness of alternative polio immunization policies in South Africa.

Griffiths UK, Botham L, Schoub BD.

Vaccine. 2006 Jul 17;24(29-30):5670-8.

PMID:
16766096
4.

Anomalous observations on IPV and OPV vaccination.

John TJ.

Dev Biol (Basel). 2001;105:197-208.

PMID:
11763328
5.
6.

The role of routine polio immunization in the post-certification era.

Sutter RW, Cáceres VM, Mas Lago P.

Bull World Health Organ. 2004 Jan;82(1):31-9. Epub 2004 Feb 26.

7.

Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia.

Tucker AW, Isaacs D, Burgess M.

Aust N Z J Public Health. 2001 Oct;25(5):411-6.

PMID:
11688618
8.

A developing country perspective on vaccine-associated paralytic poliomyelitis.

John TJ.

Bull World Health Organ. 2004 Jan;82(1):53-7; discussion 57-8. Epub 2004 Feb 26.

9.

Possible global strategies for stopping polio vaccination and how they could be harmonized.

Cochi SL, Sutter RW, Aylward RB.

Dev Biol (Basel). 2001;105:153-8; discussion 159.

PMID:
11763323
11.

The costs of future polio risk management policies.

Tebbens RJ, Sangrujee N, Thompson KM.

Risk Anal. 2006 Dec;26(6):1507-31.

PMID:
17184394
12.

Poliomyelitis: eradication in sight.

Melnick JL.

Epidemiol Infect. 1992 Feb;108(1):1-18. Review.

13.

Polio immunization policy in Mexico: economic assessment of current practice and future alternatives.

Mascareñas A, Salinas J, Tasset-Tisseau A, Mascareñas C, Khan MM.

Public Health. 2005 Jun;119(6):542-9.

PMID:
15826896
14.

The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox.

Heinsbroek E, Ruitenberg EJ.

Vaccine. 2010 May 14;28(22):3778-83. doi: 10.1016/j.vaccine.2010.02.095. Epub 2010 Apr 1. Review.

PMID:
20362626
15.

Polio eradication: the OPV paradox.

Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ.

Rev Med Virol. 2003 Sep-Oct;13(5):277-91. Review.

PMID:
12931339
16.

Epidemiology of poliomyelitis--options and update.

Dutta A.

Vaccine. 2008 Oct 23;26(45):5767-73. doi: 10.1016/j.vaccine.2008.07.101. Epub 2008 Aug 26. Review.

PMID:
18755232
17.

[The perspective of global eradication of poliomyelitis].

Knolle H, Egli A, Candrian U.

Gesundheitswesen. 2004 Jan;66(1):1-6. German.

PMID:
14767784
18.

World wide experience with inactivated poliovirus vaccine.

Bonnet MC, Dutta A.

Vaccine. 2008 Sep 15;26(39):4978-83. doi: 10.1016/j.vaccine.2008.07.026. Epub 2008 Aug 3. Review.

PMID:
18680777
19.

Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.

Khan MM, Sharma S, Tripathi B, Alvarez FP.

Public Health. 2017 Jan;142:31-38. doi: 10.1016/j.puhe.2016.10.016. Epub 2016 Nov 17.

PMID:
28057194
20.

Towards global poliomyelitis eradication: the successes and challenges for a developed country.

Wood N, Thorley B.

J Paediatr Child Health. 2003 Dec;39(9):647-50. Review.

PMID:
14629492

Supplemental Content

Support Center